ESC Congress 2026 Abstract
Evolocumab reduced first heart attacks in high-risk patients
Estimated five-year first heart attack rates were 2.7% with evolocumab and 4.1% with placebo, with a 36% relative reduction in risk.Estimated five-year first heart attack rates were 2.7% with evolocumab and 4.1% with placebo, with a 36% relative reduction in risk.
Randomized trial · 12,257 peopleEvolocumab
Who was studied12,257 patients with atherosclerosis or high-risk diabetes, against placebo
What changedFirst heart attack risk was 36% lower with evolocumab than with placebo
The catchThe abstract did not report adverse-event results